AMRXAmneal Pharmaceuticals, Inc.
$19.92+103% 1Y
$19.92
$9.6052 weeks$20.49
AMRX in its own filings
AMRX's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
190
Events found in the filings · across 692 filings · the record starts in 2017
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 10, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 19, 2017
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 29, 2026
- Change in certifying accountanthistorical
- 2018-05-07
- Delisting notice / listing-rule failurepast_3y
- 2023-12-15
- Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares
- 2023-12-26
- SEC comment-letter activity12 occurrences
- 2022-08-05
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 10, 2026The information set forth under the Introductory Note of this Report is incorporated into this.Material agreement entered · Form 8-K
- Aug 3, 2026On August 3, 2026, Amneal Pharmaceuticals, Inc.’s (the "Corporation") subsidiary, Amneal Pharmaceuticals LLC (the “Company”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 3 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan Chase Bank, N.A., as …Material agreement entered · Form 8-K
- Jul 30, 2026Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18.Earnings release · press release
- May 7, 2026‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒.Earnings release · press release
- Apr 22, 2026Membership Interest Purchase Agreement On April 21, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Amneal”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Kashiv BioSciences, LLC (“Kashiv”), KB Seller Representative, LLC (the “Seller …Material agreement entered · Form 8-K
- Feb 27, 2026‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth.Earnings release · press release
- Feb 3, 2026On February 2, 2026, Amneal Pharmaceuticals, Inc.’s (the "Corporation") subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Borrower”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 2 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan …Material agreement entered · Form 8-K
- Jan 28, 2026On January 23, 2026, Amneal Pharmaceuticals, Inc. (the “Company”) determined that it will make effective its nationwide agreement to settle a substantial majority of the opioids-related claims brought against the Company by various states and subdivisions (the “Nationwide Opioids Settlement Agreement”), having …Other event · Form 8-K
- Oct 30, 2025‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, Specialty & Generic
Ranks #16 of 41 by RyuScore